{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017458","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.788602+00:00","generated_at":"2026-06-15T22:49:41.749630+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera reports Q1 net loss of $40.9M, cash $516M; initiates MDM2 degrader trial","bullets":["Net loss $40.9M vs $36.7M Q1 2022; R&D expenses $42.2M (up from $35.9M).","Cash and investments $516M as of March 31, 2023; runway into H2 2025.","Phase 1 trial of MDM2 degrader KT-253 initiated in relapsed/refractory myeloid malignancies and solid tumors.","KT-474 (IRAK4 degrader) Phase 2 planned in hidradenitis suppurativa for 2023; Phase 1 data at EADV May 18.","KT-333 and KT-413 Phase 1 updates at ICML in June; anti-tumor activity data expected later in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017458","json":"https://secwatch.observer/filing/0000950170-23-017458.json","markdown":"https://secwatch.observer/filing/0000950170-23-017458.md","text":"https://secwatch.observer/filing/0000950170-23-017458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023017458/0000950170-23-017458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023017458/kymr-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:49:41.749630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88f51684d08fbb2de6000e48650f1ea6b1846bc0","claim":"Kymera Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 4, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023017458/0000950170-23-017458-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}